Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

US10093684B2 · kind B2 · utility

Assignee

• GILEAD CONNECTICUT, INC. · US

Inventors

• Peter A. Blomgren · Issaquah, US
• Kevin S. Currie · North Branford, US
• Jeffrey E. Kropf · Branford, US
• Seung H. Lee · Sammamish, US
• Scott A. Mitchell · East Haven, US
• Douglas G. Stafford · Niskayuna, US
• Jianjun Xu · Bellevue, US

Key dates

• Filing date: Jan 11, 2017
• Grant date: Oct 9, 2018
• Expiry date: Jan 11, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/9121
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Certain imidazopyrazines of Formula I and pharmaceutical compositions thereof are provided herein: Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.